arrow
R

Rom S. Leidner

Providence Cancer Institute
H指数:33
被引数:6,118

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Intratumoral delivery of PD-1/PD-L1 and CTLA-4 inhibitors for recurrent/refractory solid tumors: a proof-of-concept treatment strategy

PD-1/PD-L1和CTLA-4抑制剂在复发性/难治性实体瘤中的瘤内递送:一种概念验证治疗策略

2025-12-120
OAAI
Phenotypic and clonal evolution of CD4 T cells in HNSCC during immunotherapy: a case report
2025-11-010
PRE
Identification of a TCR to a non-canonical peptide (NCP) presented by the autologous non-small cell lung cancer (NSCLC) following an immunotherapy that includes canonical and NCPs 3338
2025-11-010
PRE
AFNT-211: A phase1 study of autologous CD4+and CD8+T cells engineered to express a high avidity HLA-A*11:01-restricted, KRAS G12V-specific, transgenic TCR; CD8α/β coreceptor; and a FAS41BB switch receptor in patients with advanced/metastatic solid tumors
2024-04-050
PRE
An off-the-shelf multivalent vaccine containing cancer's dark matter, DPV-001, combined with PD-1+/- GITR in head & neck cancer: safety, efficacy, and immunodynamics from the phase 1 GITRVax trial
2024-04-050
PRE
First-in-human phase I/Ib study of NIZ985, a recombinant heterodimer of IL-15 and IL-15Rα, as a single agent and in combination with spartalizumab in patients with advanced and metastatic solid tumors
2023-10-315
OAAI
Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 1st-3rd, 2022-Naples, Italy)

黑色素瘤的观点: 黑色素瘤桥会议报告 (2022年12月1至3日-意大利那不勒斯)

2023-07-282
OAAI
Crizotinib (C) in patients (pts) with solid tumors with MET amplification (amp) or mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study
2023-04-140
PRE
Trial in progress: First-in-human immunotherapy-trio for advanced head and neck squamous cell carcinoma
2023-04-140
PRE
Multi-parametric comparison of scRNA-seq with CITE-seq and ultrahigh-plex spatial phenotyping of proteins in FFPE head and neck tumor biopsies: An opportunity to generate uniquely comprehensive multi-omic single cell datasets to investigate the tumor microenvironment
2023-04-040
PRE
Safety of Nivolumab Added to Chemoradiation Therapy Platforms for Intermediate and High-Risk Locoregionally Advanced Head and Neck Squamous Cell Carcinoma: RTOG Foundation 3504
2023-03-016
OAAI